MarginsXMarginsX
Home › Markets › Health Care › OTLK

Outlook Therapeutics Inc. (OTLK)

OTLK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3960
-4.12% on the day
Market cap
$96.4M
Micro cap
Revenue · 2025
$1.4M
Prior year not contiguous
Net income · 2025
-$62.4M
-4416.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/0001104659-25-123264-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.

Profile

FieldValue
TickerOTLK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2016
SEC CIK0001649989
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.4M
Net income-$62.4M
Operating income-$67.1M
Net margin-4416.2%
Operating margin-4744.3%
Revenue growthNo prior-year revenue to compare
Cash$8.1M
Total assets$18.6M
P/E (computed)Net income was not positive
P/S (computed)68.2×

Warning signs

Cash runway
2.4 months
$11.2M cash at June 30, 2026
Share count, 1 year
+448.1%
2025-08-11 to 2026-08-14 · +1770.9% over 3 years
Going-concern doubt
Yes
10-Q filed August 18, 2026
Insider net buying, 12 months
$7.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result of the above factors, there is substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-18
Cash and burn$11.2M cash; operating cash flow -$14.0M a quarter.Report 2026-06-30
Shares outstanding243,447,554 (2026-08-14); 44,419,529 a year earlier; 260,245,017 three years earlier. 3y figure adjusted for splits (1-for-20 overall).Cover page 2026-08-14
Reverse splits, 3 years1; latest 1-for-20 on 2024-03-14Source 2024-03-14
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 7 424B5 takedowns, 7 at the marketLatest 2026-08-14
Exchange deficiency notices, 12 months3 (8-K item 3.01)8-K 2026-09-30
AuditorKPMG LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-01-13
Late filings, 12 months1 NT noticeNT 10-Q 2026-08-17
Insider trades, 12 monthsBought $7.9M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
Not filed-$20.3M-$21.0M$11.2MNo debt tagsNeeds four quarters10-Q 2026-08-18
Q2 2026
2026-03-31
Not filed-$4.5M-$7.8M$7.7MNo debt tagsNeeds four quarters10-Q 2026-08-18
Q1 2026
2025-12-31
Not filed-$23.1M-$14.9M$8.7MNo debt tagsNeeds four quarters10-Q 2026-08-18
Q4 2025
2025-09-30
-$92K-$13.3M-$12.4M$8.1M$29.9M$1.4M10-K 2025-12-19
Q3 2025
2025-06-30
$1.5M-$20.2M-$11.9M$8.9MNo debt tagsNeeds four quarters10-Q 2025-08-14
Q2 2025
2025-03-31
Not filed-$46.4M-$16.6M$7.6MNo debt tagsNeeds four quarters10-Q 2026-08-18
Q1 2025
2024-12-31
Not filed$17.4M-$11.0M$5.7MNo debt tagsNeeds four quarters10-Q 2026-08-18
Q4 2024
2024-09-30
Not filed$5.7M-$17.0M$14.9MNo debt tagsNeeds four quarters10-K 2025-12-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-14
Latest annual report10-K2025-12-19
Latest quarterly / interim10-Q2026-08-18
Latest current report
FORM 8-K
8-K2026-09-30
Latest proxyDEFA14A2026-07-10

Source: SEC EDGAR submissions feed, 834 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.3%
1 month-26.8%
3 months-53.5%
Year to date-73.9%
1 year-71.9%
From 52-week high-83.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
MOLNMolecular Partners AG$2.70-8.21%$101.2M
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
ZURAZura Bio Limited$1.08-12.90%$104.0M
BDTXBlack Diamond Therapeutics Inc.$1.53+4.08%$87.9M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
CHRSCoherus Oncology Inc.$0.5059-3.73%$78.2M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier